Experts agree that the incoming Trump administration will likely shake things up in the prescription drug world — most notably when it comes to research and development, drug pricing and PBM reform.
Multiple stakeholders are to blame for prescription drug costs, including pharmaceutical companies and PBMs, according to Merith Basey, executive director of Patients for Affordable Drugs.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
AbbVie announced plans to acquire Immunogen — and the biotech’s recently approved ADC treatment for ovarian cancer — for $10.1 billion in cash. The pharma giant is diving into ADCs again after a previous multibillion-dollar acquisition of a different ADC drugmaker ended up failing a few years ago.
Merith Basey, executive director of Patients For Affordable Drugs, believes the Medicare price negotiation program is here to stay, no matter who is president and no matter how many Big Pharma players file lawsuits. Her reasoning? Every other high income nation has been negotiating prices with drugmakers for years, and the program is widely popular in the U.S. among pretty much everyone who isn’t a pharma company, she said during a session at Engage at HLTH.
Generic drugmakers Teva and Glenmark recently became the sixth and seventh drugmakers to resolve criminal charges as a result of the DOJ’s yearslong investigation into generic drug price fixing. The settlement agreement requires both companies to pay hefty fines as well as divest their drug lines for pravastatin, a widely used statin that lowers cholesterol.
Lawsuits filed in opposition to the White House's drug pricing negotiation program are beginning to mount, but legal experts agree that the plaintiffs’ arguments probably won’t hold up during a court battle. However, these lawsuits still could delay when the government's ability to negotiate price goes into effect.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
America’s Health Insurance Plans' new campaign aims to show how health insurers are working to create savings for Americans while also targeting Big Pharma (or more specifically drug manufacturers) for increasing drug costs. The ads will be distributed on TV, social media and streaming services.
The quest to develop a cure for Covid-19 has been a historic journey so far, driven by hope and urgency, with a mix of disappointing setbacks and encouraging progress.
This eBook offers an overview of drug patents that were and are set to expire and highlights efforts by the FDA to stimulate the market for generics.
On an earnings call, Cigna CEO David Cordani seemed largely nonplussed about the potential rule's impact on the company's bottom line, even after the insurer's blockbuster acquisition of Express Scripts.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
It may seem daunting, but consumers can take action. Call or write your elected officials and fight back economically by researching discount options at retail pharmacies.
Biotech dealmaking such as the one by J&J underscore big pharma's hunt for new markets as opposed to making synergies the primary purpose to drive growth.
At a breakfast reception during the ongoing J.P. Morgan Healthcare Conference, the mood around the prospects for Big Pharma in 2017 was downright gloomy.
Nine out of 10 large pharma companies spend more on marketing than they do on R&D. It's a statistic often cited as a sign of industry greed, but it may be the best way to foster real innovation.
Bernie Sanders appeared on Real Time with Bill Maher to charge that Big Pharma spends more money on marketing and advertising than on research and development. Was he right?